Janssen Pharmaceuticals, Inc.

Janssen Pharmaceutica Nv

Laureate Institute for Brain Research

Wayne C Drevets

Srihari Gopal

Adam Savitz

Vanina Popova

Mark Schmidt

Iva Kezic

Rama Melkote

Darrel Pemberton

Chakradhar Lagishetty

Jaskaran Singh

Frank Wiegand

Ella Daly

Margaret Fedgchin

Justine M Kent

Lodewijk Ivo Caers

Carla Marie Canuso

Peter Nicholas Zannikos

Peter De Boer

Philippe Fernandes

Nicolaas Martha Felix Goyvaerts

Qingqin S Li

Geert Van Der Avoort

David Wood Hough

Mahesh N Samtani

William Robert Yates

Jonathan Bradley Savitz

Sheldon H Preskorn

Honglan Li

Ewa Wajs

Matthieu Ravelingien

Katarina Jokicevic

Laura Martinez Marcos

Tom Huybrechts

Tatiana Marcozzi

The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

Compositions and methods for the treatment of depression

The present disclosure relates to compositions, including oral compositions in the form of tablets, comprising aticaprant and methods of using the same.

Compositions comprising aticaprant

The present disclosure is directed to, inter alia, methods of treating a subject suffering from or diagnosed with depression, comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Rto Rare described herein and wherein the compound is administered prior to sleep.

Methods of treating depression using orexin-2 receptor antagonists

The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.

Forms of aticaprant

The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.

Esketamine for the treatment of depression

The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations).

Methods for the treatment of depression

The present disclosure is directed to, inter alia, methods of treating a subject suffering from or diagnosed with depression, comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Rto Rare described herein and wherein the compound is administered prior to sleep. 

Growing community of inventors

Rancho Santa Fe, CA, United States of America

Wayne C Drevets